Trial Profile
A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs MK-2118 (Primary) ; MK-2118 (Primary) ; Pembrolizumab (Primary)
- Indications Cutaneous T-cell lymphoma; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 23 Jan 2023 Status changed from active, no longer recruiting to completed.
- 17 Nov 2022 Planned End Date changed from 10 May 2023 to 5 Jan 2023.
- 17 Nov 2022 Planned primary completion date changed from 10 May 2023 to 5 Jan 2023.